exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Company profile
Ticker
XCUR
Exchange
Website
CEO
David Giljohann
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Max-1 Acquisition Corp
SEC CIK
Corporate docs
Subsidiaries
Exicure Operating Company ...
XCUR stock data
Latest filings (excl ownership)
8-K
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
22 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Jan 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
1 Dec 23
8-K
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
28 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
Other Events
6 Oct 23
8-K
Departure of Directors or Certain Officers
27 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Sep 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.54 mm | 3.54 mm | 3.54 mm | 3.54 mm | 3.54 mm | 3.54 mm |
Cash burn (monthly) | 2.54 mm | 1.57 mm | 1.92 mm | (no burn) | 1.60 mm | 1.83 mm |
Cash used (since last report) | 25.16 mm | 15.56 mm | 19.02 mm | n/a | 15.88 mm | 18.11 mm |
Cash remaining | -21.63 mm | -12.03 mm | -15.49 mm | n/a | -12.34 mm | -14.58 mm |
Runway (months of cash) | -8.5 | -7.7 | -8.1 | n/a | -7.7 | -8.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 709.42 mm |
Total shares | 8.84 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Gates Ventures | 4.84 mm | $1.17 mm |
CBI USA | 3.40 mm | $3.98 mm |
CG Carlyle Group Inc | 281.64 k | $368.94 mm |
Carlson Capital L P | 125.00 k | $163.75 mm |
Renaissance Technologies | 62.90 k | $82.00 k |
Citadel Advisors | 50.35 k | $65.96 mm |
Vanguard | 34.32 k | $44.96 mm |
Geode Capital Management | 21.64 k | $28.35 mm |
BLK Blackrock | 12.33 k | $16.15 mm |
Tower Research Capital | 6.78 k | $8.88 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | DGP | Common Stock | Sell | Dispose S | No | No | 1.32 | 3,400,000 | 4.49 mm | 0 |
16 Feb 24 | Josh Miller | Common Stock | Payment of exercise | Dispose F | No | No | 0.5978 | 46 | 27.50 | 1,827 |
16 Nov 23 | Josh Miller | Common Stock | Payment of exercise | Dispose F | No | No | 0.565 | 38 | 21.47 | 1,873 |
News
5 Value Stocks In The Healthcare Sector
26 Feb 24
5 Value Stocks In The Healthcare Sector
19 Feb 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
8 Feb 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 Feb 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
6 Feb 24